Our History

We develop products and technologies that help protect consumers from dangerous infections.

Our foundational technology, originally invented at NASA’s Jet Propulsion Laboratory, integrates cutting-edge optical physics, chemistry spectroscopy, and molecular biology. Based on scientific expertise and close partnership with quality management professionals, Verrix is developing break through solutions for sterility assurance, environmental monitoring, and infection control.

Invented at NASA, developed for industry.

Our Story Timeline

2001 – 2013

Verrix was formed as a spinoff from the Jet Propulsion Laboratory (JPL), and is partnered with JPL PhDs and scientists to commercialize a library of issued patents licensed from the California Institute of Technology (Caltech). Our foundational technology integrates cutting-edge optical physics, chemistry, spectroscopy and molecular biology, and is uniquely positioned to critical unmet needs for protecting patients from life threatening infections.

2004 – 2008

The Ponce Group performs astrobiology experiments on Arctic and Antarctic ices and desert soils using the first-generation EVA reader.


The first patent is issued for the unique method of spore detection that serves as the basis for Verrix technology. In total, a library of seven US patents and one European patent support the foundational Verrix technology.


Verrix, LLC is established as a standalone company to develop breakthrough technology for the healthcare market. Dr. Ponce builds a research lab in his home garage with Small Business Innovation Research funding from the EPA to continue development of the novel rapid detection technology.


With research grant funding from Caltech and investor seed funding the company moves into the Pasadena Bioscience Collaborative Incubator (PBC).


Verrix expands from two scientists sharing a single bench to a fulltime staff of five occupying an office and three benches. PCB affords Verrix access to top of the line equipment and a rich environment of support as the team continues to develop the foundational technology into a viable commercial product.


Verrix closes a Series A round of funding for technology and product development. The company expands its board of directors to include healthcare industry veterans Cameron Rouns and John Buhler who are both experienced in bringing transformational medical device products to market.


Cameron Rouns is appointed Chief Executive Officer. Verrix moves its headquarters to San Clemente, CA. The 10,000 square foot facility boasts laboratory, manufacturing and office space for the growing team. The location is amidst Orange County’s thriving community of healthcare and technology development, giving the company access to a rich pool of technical and commercial talent.


The company successfully sells 100% of its healthcare assets to a leading global healthcare provider and retains product and patent rights to market its technology to a broad set of industries outside healthcare, biomedical, pharmaceutical, and life science.